{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:39:13Z","timestamp":1790735953178,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S000852\/1"],"award-info":[{"award-number":["MR\/S000852\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["(Award number MR\/T025573\/1)"],"award-info":[{"award-number":["(Award number MR\/T025573\/1)"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Kidney transplantation is the gold-standard treatment for patients with kidney failure. However, one-third of patients awaiting a kidney transplant are highly sensitized to human leukocyte antigens (HLA), resulting in an increased waiting time for a suitable kidney, more acute and chronic rejection, and a shorter graft survival compared to non-highly sensitised patients. Current standard immunosuppression protocols do not adequately suppress memory responses, and so alternative strategies are needed. Autologous polyclonally expanded regulatory T cells (Tregs) have been demonstrated to be safe in transplant settings and could be a potential alternative to modulate memory immune alloresponses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The aim of this trial is to determine whether adoptive transfer of autologous Tregs into HLA sensitised patients can suppress memory T and B cell responses against specific HLA antigens. This is a two-part, multi-centre, prospective clinical trial, comprising an observational phase (Part 1) aiming to identify patients with unregulated cellular memory responses to HLA (Pure HLA Proteins) followed by an interventional phase (Part 2). The first 9 patients identified as being eligible in Part 1 will undergo baseline immune monitoring for 2\u00a0months to inform statistical analysis of the primary endpoint. Part 2 is an adaptive, open labelled trial based on Simon\u2019s two-stage design, with 21 patients receiving Good Manufacturing Practice (GMP)-grade polyclonally expanded Tregs to a dose of 5\u201310\u2009\u00d7\u2009106 cells\/kg body weight. The primary EP is suppression of in vitro memory responses for 2\u00a0months post-infusion. 12 patients will receive treatment in stage 1 of Part 2, and 9 patients will receive treatment in stage 2 of Part 2 if\u2009\u2265\u200950% patients pass the primary EP in stage 1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This is a prospective study aiming to identify patients with unregulated cellular memory responses to Pure HLA Proteins and determine baseline variation in these patterns of response. Part 2 will be an adaptive phase IIa clinical trial with 21 patients receiving a single infusion of GMP-grade polyclonally expanded Tregs in two stages. It remains to be demonstrated that modulating memory alloresponses clinically using Treg therapy is achievable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT Number: 2021\u2013001,664-23.<\/jats:p>\n                <jats:p>REC Number: 21\/SC\/0253.<\/jats:p>\n                <jats:p>Trial registration number ISRCTN14582152.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03157-7","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:02:29Z","timestamp":1682658149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Can regulatory T cells improve outcomes of sensitised patients after HLA-Ab incompatible renal transplantation: study protocol for the Phase IIa GAMECHANgER-1 trial"],"prefix":"10.1186","volume":"24","author":[{"given":"C","family":"Dudreuilh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Beadle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Pilecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Scott\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Mamode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DS","family":"Game","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sanchez-Fueyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Learoyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Douiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dorling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"12","key":"3157_CR1","doi-asserted-by":"publisher","first-page":"e13751","DOI":"10.1111\/ctr.13751","volume":"33","author":"CA Schinstock","year":"2019","unstructured":"Schinstock CA, Smith BH, Montgomery RA, Jordan SC, Bentall AJ, Mai M, et al. Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization? Clin Transplant. 2019;33(12):e13751.","journal-title":"Clin Transplant"},{"issue":"10070","key":"3157_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(16)31595-1","volume":"389","author":"M Manook","year":"2017","unstructured":"Manook M, Koeser L, Ahmed Z, Robb M, Johnson R, Shaw O, et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. The Lancet. 2017;389(10070):727\u201334.","journal-title":"The Lancet"},{"issue":"10","key":"3157_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/tri.12621","volume":"28","author":"L Couzi","year":"2015","unstructured":"Couzi L, Manook M, Perera R, Shaw O, Ahmed Z, Kessaris N, et al. Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations. Transpl Int. 2015;28(10):1205\u201315.","journal-title":"Transpl Int"},{"issue":"5","key":"3157_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMoa1612567","volume":"377","author":"SC Jordan","year":"2017","unstructured":"Jordan SC, Lorant T, Choi J, Kjellman C, Winstedt L, Bengtsson M, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017;377(5):442\u201353.","journal-title":"N Engl J Med"},{"issue":"12","key":"3157_CR5","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1111\/ajt.16754","volume":"21","author":"C Kjellman","year":"2021","unstructured":"Kjellman C, Maldonado AQ, Sj\u00f6holm K, Lonze BE, Montgomery RA, Runstr\u00f6m A, et al. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant. 2021;21(12):3907\u201318.","journal-title":"Am J Transplant"},{"issue":"3","key":"3157_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","volume":"146","author":"DD Patel","year":"2020","unstructured":"Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. J Allergy Clin Immunol. 2020;146(3):467\u201378.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"3157_CR7","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1097\/TXD.0000000000000695","volume":"3","author":"L Pankhurst","year":"2017","unstructured":"Pankhurst L, Hudson A, Mumford L, Willicombe M, Galliford J, Shaw O, et al. The UK National Registry of ABO and HLA Antibody Incompatible Renal Transplantation: Pretransplant Factors Associated With Outcome in 879 Transplants. Transplant Direct. 2017;3(7):e181.","journal-title":"Transplant Direct"},{"issue":"8","key":"3157_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","volume":"16","author":"H Fraser","year":"2018","unstructured":"Fraser H, Safinia N, Grageda N, Thirkell S, Lowe K, Fry LJ, et al. A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. Molecular Therapy Methods & Clinical Development. 2018;16(8):198\u2013209.","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"4","key":"3157_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/ajt.15700","volume":"20","author":"A S\u00e1nchez-Fueyo","year":"2020","unstructured":"S\u00e1nchez-Fueyo A, Whitehouse G, Grageda N, Cramp ME, Lim TY, Romano M, et al. Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation. Am J Transplant. 2020;20(4):1125\u201336.","journal-title":"Am J Transplant"},{"key":"3157_CR10","doi-asserted-by":"crossref","unstructured":"Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials. Lancet. 2020 23;395(10237):1627\u201339.","DOI":"10.1016\/S0140-6736(20)30167-7"},{"issue":"4","key":"3157_CR11","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/ajt.16395","volume":"21","author":"PN Harden","year":"2021","unstructured":"Harden PN, Game DS, Sawitzki B, Van der Net JB, Hester J, Bushell A, et al. Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients. Am J Transplant. 2021;21(4):1603\u201311.","journal-title":"Am J Transplant"},{"issue":"10","key":"3157_CR12","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.4049\/jimmunol.180.10.6640","volume":"180","author":"M Carvalho-Gaspar","year":"2008","unstructured":"Carvalho-Gaspar M, Jones ND, Luo S, Martin L, Brook MO, Wood KJ. Location and Time-Dependent Control of Rejection by Regulatory T Cells Culminates in a Failure to Generate Memory T Cells. J Immunol. 2008;180(10):6640\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"3157_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/ki.2015.100","volume":"88","author":"KY Shiu","year":"2015","unstructured":"Shiu KY, McLaughlin L, Rebollo-Mesa I, Zhao J, Semik V, Terence Cook H, et al. B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection. Kidney Int. 2015;88(3):560\u20138.","journal-title":"Kidney Int"},{"key":"3157_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fimmu.2020.00079","volume":"11","author":"KY Shiu","year":"2020","unstructured":"Shiu KY, Stringer D, McLaughlin L, Shaw O, Brookes P, Burton H, et al. Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts. Front Immunol. 2020;11:79.","journal-title":"Front Immunol"},{"issue":"2","key":"3157_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.kint.2016.10.009","volume":"91","author":"KY Shiu","year":"2017","unstructured":"Shiu KY, McLaughlin L, Rebollo-Mesa I, Zhao J, Burton H, Douthwaite H, et al. Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell\u2013dependent indirect antidonor alloresponses and autocrine regulation of interferon-\u03b3 production by Th1 cells. Kidney Int. 2017;91(2):477\u201392.","journal-title":"Kidney Int"},{"issue":"7","key":"3157_CR16","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/j.1600-6143.2007.01842.x","volume":"7","author":"W Gao","year":"2007","unstructured":"Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007;7(7):1722\u201332.","journal-title":"Am J Transplant"},{"issue":"2","key":"3157_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.TP.0000101005.44661.3E","volume":"77","author":"L Tian","year":"2004","unstructured":"Tian L, Lu L, Yuan Z, Lamb JR, Tam PKH. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation. 2004;77(2):183\u20139.","journal-title":"Transplantation"},{"issue":"3","key":"3157_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1600-6143.2005.00758.x","volume":"5","author":"DS Game","year":"2005","unstructured":"Game DS, Hernandez-Fuentes MP, Lechler RI. Everolimus and Basiliximab Permit Suppression by Human CD4 + CD25 + Cells in vitro. Am J Transplant. 2005;5(3):454\u201364.","journal-title":"Am J Transplant"},{"issue":"9","key":"3157_CR19","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.4049\/jimmunol.180.9.5794","volume":"180","author":"S Basu","year":"2008","unstructured":"Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol. 2008;180(9):5794\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"3157_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2007-06-094482","volume":"111","author":"R Zeiser","year":"2008","unstructured":"Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111(1):453\u201362.","journal-title":"Blood"},{"key":"3157_CR21","doi-asserted-by":"publisher","unstructured":"Brook MO, Hester J, Petchey W, Rombach I, Dutton S, Bottomley MJ, Black J, Abdul Wahab S, Bushell A, Lombardi G, Wood K, Friend P, Harden P, Issa F. Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients. BMJ Open. 2022 Apr 15;12(4):e061864. doi: https:\/\/doi.org\/10.1136\/bmjopen-2022-061864.","DOI":"10.1136\/bmjopen-2022-061864"},{"issue":"50","key":"3157_CR22","doi-asserted-by":"publisher","first-page":"19954","DOI":"10.1073\/pnas.0704397104","volume":"104","author":"J Yang","year":"2007","unstructured":"Yang J, Brook MO, Carvalho-Gaspar M, Zhang J, Ramon HE, Sayegh MH, et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A. 2007;104(50):19954\u20139. https:\/\/doi.org\/10.1073\/pnas.0704397104. (Epub 2007 Nov 27).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3157_CR23","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/j.1600-6143.2011.03635.x","volume":"11","author":"B Afzali","year":"2011","unstructured":"Afzali B, Mitchell PJ, Scott\u00e0 C, Canavan J, Edozie FC, Fazekasova H, Lord GM, John S, Barber LD, Hernandez-Fuentes MP, Lechler RI, Lombardi G. Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells. Am J Transplant. 2011;11(8):1734\u201342. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03635.x.","journal-title":"Am J Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03157-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03157-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03157-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:02:42Z","timestamp":1682658162000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03157-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3157"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03157-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial will be conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of Good Clinical Practice and in accordance with all applicable regulatory requirements including but not limited to the Research Governance Framework and the Medicines for Human Use (Clinical Trial) Regulations 2004, as amended in 2006 and any subsequent amendments. This protocol and related documents have been approved by the South Central \u2013 Oxford A Research Ethics Committee (REC ref number: 21\/SC\/0253) and authorised by the Medicines and Healthcare products Regulatory Agency. Patients will be asked to provide written 'informed' consent\u00a0to inclusion in both Part 1 and Part 2 of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}